证券代码：430047 证券简称：诺思兰德 公告编号：2025-095 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 授权委托理财情况 （一）审议情况 北京诺思兰德生物技术股份有限公司（以下简称"公司"）于 2025 年 7 月 21 日召开第六届董事会第十九次会议，审议通过了《关于使用部分闲置自有资 金委托理财的议案》。为了提高公司的自有闲置资金利用率，增加投资收益，在 不影响公司主营业务的正常发展，并确保公司经营需求的前提下，公司拟使用人 民币不超过 10,000 万元的自有闲置资金购买安全性高、流动性好的理财产品（包 括但不限于向金融机构购买通知存款、结构性存款、银行定期存单等产品），拟 投资的产品期限最长不超过 12 个月。在前述额度内，资金可以循环滚动使用， 使用期限为自公司董事会审议通过之日起 12 个月内有效，如单笔产品的存续期 超过董事会决议有效期，则决议的有效期自动顺延至该笔交易终止之日止。 具体内容详见公司 2025 年 7 月 21 日在北京证券交易所指定信息披露平台 （h ...

证券代码：430047 证券简称：诺思兰德 公告编号：2025-093 北京诺思兰德生物技术股份有限公司 关于使用部分闲置自有资金委托理财的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 授权委托理财情况 （一）审议情况 北京诺思兰德生物技术股份有限公司（以下简称"公司"）于 2025 年 7 月 21 日召开第六届董事会第十九次会议，审议通过了《关于使用部分闲置自有资 金委托理财的议案》。为了提高公司的自有闲置资金利用率，增加投资收益，在 不影响公司主营业务的正常发展，并确保公司经营需求的前提下，公司拟使用人 民币不超过 10,000 万元的自有闲置资金购买安全性高、流动性好的理财产品（包 括但不限于向金融机构购买通知存款、结构性存款、银行定期存单等产品），拟 投资的产品期限最长不超过 12 个月。在前述额度内，资金可以循环滚动使用， 使用期限为自公司董事会审议通过之日起 12 个月内有效，如单笔产品的存续期 超过董事会决议有效期，则决议的有效期自动顺延至该笔交易终止之日止。 具体内容 ...

证券代码：430047 证券简称：诺思兰德 公告编号：2025-092 北京诺思兰德生物技术股份有限公司 关于使用部分闲置自有资金委托理财的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 授权委托理财情况 （一）审议情况 北京诺思兰德生物技术股份有限公司（以下简称"公司"）于 2025 年 7 月 21 日召开第六届董事会第十九次会议，审议通过了《关于使用部分闲置自有资 金委托理财的议案》。为了提高公司的自有闲置资金利用率，增加投资收益，在 不影响公司主营业务的正常发展，并确保公司经营需求的前提下，公司拟使用人 民币不超过 10,000 万元的自有闲置资金购买安全性高、流动性好的理财产品（包 括但不限于向金融机构购买通知存款、结构性存款、银行定期存单等产品），拟 投资的产品期限最长不超过 12 个月。在前述额度内，资金可以循环滚动使用， 使用期限为自公司董事会审议通过之日起 12 个月内有效，如单笔产品的存续期 超过董事会决议有效期，则决议的有效期自动顺延至该笔交易终止之日止。 具体内容 ...

Core Viewpoint - The biopharmaceutical sector experienced a significant increase of 3.06% on September 5, with Sanofi leading the gains [1] Group 1: Market Performance - The Shanghai Composite Index closed at 3812.51, up 1.24% [1] - The Shenzhen Component Index closed at 12590.56, up 3.89% [1] Group 2: Individual Stock Performance - Sanofi (688336) closed at 61.60, with a rise of 11.80% and a trading volume of 165,400 shares, totaling a transaction value of 9.62 billion [1] - Changchun High-tech (000661) closed at 128.00, increasing by 7.53% with a trading volume of 270,100 shares [1] - Junshi Biosciences (688180) closed at 48.00, up 7.38% with a trading volume of 252,900 shares, totaling 1.17 billion [1] - Tibet Pharmaceutical (600211) closed at 50.48, rising by 7.13% with a trading volume of 220,200 shares, totaling 1.08 billion [1] - Other notable stocks include: - Rongan Bio (688331) at 92.17, up 4.32% [1] - Kexing Pharmaceutical (688136) at 42.27, up 4.14% [1] Group 3: Capital Flow - The biopharmaceutical sector saw a net inflow of 231 million from institutional investors, while retail investors experienced a net outflow of 25.77 million [1]

中泰证券股份有限公司 关于北京诺思兰德生物技术股份有限公司 2025 年半年度持续督导跟踪报告 根据《证券发行上市保荐业务管理办法》《北京证券交易所股票上市规则》 等有关法律法规、规范性文件的规定，中泰证券股份有限公司（以下简称"中泰 证券"或"保荐机构"）作为北京诺思兰德生物技术股份有限公司（以下简称"诺 思兰德"或"公司"）的保荐机构，负责诺思兰德的持续督导工作，并出具 2025 年半年度持续督导跟踪报告。 | 项目 | 工作内容 | | --- | --- | | 1、审阅公司信息披露文件 | 保荐机构及时审阅公司信息披露文件。 | | 2、督导公司建立健全并有效 | 保荐机构督导公司建立健全规则制度（包括但不限于根据新 | | 执行规则制度 | 《公司法》及《上市规则》的规定，修改完善公司治理制度）， | | | 本督导期内，诺思兰德有效执行了规则制度。 | | 3、募集资金使用监督 | 保荐机构定期查阅公司募集资金账户对账单，核查公司募集 | | | 资金使用情况；前往公司现场核查募集资金使用情况。本督 | | | 导期内，诺思兰德募集资金存放与使用符合相关规定。 | | 4、督导公司规范运作 | ...

Group 1 - The biopharmaceutical sector experienced a decline of 0.64% on September 3, with Sai Sheng Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3813.56, down 1.16%, while the Shenzhen Component Index closed at 12472.0, down 0.65% [1] - Notable gainers in the biopharmaceutical sector included Baipu Sais, which rose by 12.10% to a closing price of 65.50, and Yuan Yang Crystal Sea, which increased by 9.14% to 32.95 [1] Group 2 - The net capital outflow from the biopharmaceutical sector was 446 million yuan, while retail investors saw a net inflow of 292 million yuan [3] - The table of individual stock capital flows indicates varying levels of investment activity among different companies within the sector [3]

（文章来源：证券日报） 证券日报网讯 9月1日晚间，诺思兰德发布公告称，公司第六届监事会第十六次会议审议通过了《关于 取消监事会并修订〈公司章程〉的议案》等。 ...

Core Viewpoint - The company announced the approval of multiple resolutions, including the cancellation of the supervisory board and amendments to the company's articles of association during the 22nd meeting of the sixth board of directors [2] Group 1 - The company held its 22nd meeting of the sixth board of directors on September 1 [2] - The resolutions passed include the proposal to cancel the supervisory board [2] - Amendments to the company's articles of association were also approved [2]

Group 1 - The company, Norland, announced that it will hold its second extraordinary general meeting of shareholders on September 17, 2025 [1] - The agenda for the meeting includes the proposal to cancel the supervisory board and amend the company's articles of association [1]

Meeting and Attendance - The board meeting was convened and conducted in accordance with the Company Law and the Articles of Association, with valid voting results [1] - All 9 directors were present or authorized to attend, with some participating via communication means due to work commitments [1] Agenda Review - The proposal to abolish the supervisory board and amend the Articles of Association was approved, transferring the supervisory board's powers to the audit committee of the board [1] - The original rules governing the supervisory board were simultaneously abolished, and amendments to the Articles of Association were proposed for shareholder authorization [1] Internal Management System - A proposal to establish and amend certain internal management systems was approved, aimed at enhancing corporate governance and promoting standardized operations [2][4] - This proposal includes several sub-proposals related to various management systems, such as the rules for board meetings, shareholder meetings, and related party transaction management [2][4] Shareholder Meeting - The board proposed to convene the second extraordinary general meeting of shareholders in 2025 on September 17 to review related proposals [6] - This proposal does not involve related party transactions and does not require avoidance of voting [6]